RETA (Retatrutide)

RETA (Retatrutide) is a synthetic compound that acts as a triple agonist of the GIP, GLP-1, and glucagon receptors. Each vial contains research-grade lyophilised Retatrutide, independently HPLC-tested to >99% purity by Janoshik Analytical, supplied for laboratory and scientific research purposes only. Retatrutide has been the subject of significant clinical investigation, most notably the Phase 3 TRIUMPH-4 trial, which demonstrated substantial effects on body weight reduction in participants with obesity. The compound's triple-receptor mechanism distinguishes it from earlier single- or dual-agonist research compounds. All Peptidex Retatrutide is supplied as a white to off-white lyophilised powder in a sealed, sterile glass vial. Store at -20°C for long-term storage or 2–8°C for short-term use. Reconstitute with bacteriostatic water before use. Protect from light and repeated freeze-thaw cycles. CAS Number: 2381089-83-2.